SEC Form 4 · accession 0001209191-17-004637
Pacira BioSciences, Inc. · PCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James S Scibetta
Officer — President
Period of report
Jan 17, 2017
Accepted (ET)
Jan 19, 2017 · 6:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001396814
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 17, 2017 | M | 2,373 | $1.61 | A | 29,457 | D | |
| Common Stock | Jan 17, 2017 | M | 17,627 | $5.49 | A | 47,084 | D | |
| Common StockF2 | Jan 17, 2017 | S | 15,003 | $38.39 | D | 32,081 | D | |
| Common StockF3 | Jan 17, 2017 | S | 4,997 | $38.97 | D | 27,084 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $1.61 | Jan 17, 2017 | M | 2,373 | D | — | Sep 2, 2020 | Common Stock | 2,373 | 0 | D |
| Stock Option (Right to Buy)F5 | $5.49 | Jan 17, 2017 | M | 17,627 | D | — | Dec 29, 2020 | Common Stock | 17,627 | 35,251 | D |
Explanation of responses
- F1The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.80 to $38.75, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.80 to $39.05, inclusive.
- F4The option vested as to 50% of the options on September 2, 2010 and vests as to the remaining options in successive equal monthly installments for the subsequent 24 months. The options become exercisable, to the extent vested, from and after the issuer's initial public offering.
- F5The option vests as to 25% of the option shares on December 29, 2011 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months. The option shares become exercisable, to the extent vested, from and after the Issuer's initial public offering.